Isothermal Nucleic Acid Amplification Technology Market Likely To Reach A Valuation Of Around USD 4.3 Billion By 2025:Key Participant Eiken Chemical Co. Ltd., Hologic, Inc.

San Francisco, 03 January ,  Isothermal Nucleic Acid Amplification Technology (INAAT) Market Analysis By Product, By Technology (NASBA, HDA, LAMP, SDA, SPIA, NEAR, TMA, RCA, RPA, SMAP2), And Segment Forecasts, 2018 – 2025

The global isothermalnucleic acid amplification technology (INAAT) market is expected to reach USD 4.3 billion by 2025, growing at a CAGR of 11.8%, according to a new report by Grand View Research, Inc. This can be attributed to significant rise in awareness regarding need for rapid and on-time testing for chronic and infectious diseases. Global increase in adoption of INAAT for detection of HIV, hepatitis A & B, and sexually transmitted diseases is considered to be a high impact rendering driver for growth.

Loop-Mediated Isothermal Amplification is one of the most preferred nucleic acid amplification methods because of its ability to provide point of care testing, thus leading to increased adoption. The recently-introduced Nicking Enzyme Amplification Reaction (NEAR) and Helicase-dependent amplification (HDA) technologies are expected to experience exponential growth during the forecast period owing to their patent protection.

In addition, owing to recent epidemics of infectious diseases, such as tuberculosis, Zika virus, and influenza, importance of point of care diagnosis has increased especially in developing countries. This is also anticipated to boost demand for this technology in these regions.

Access Full Research Report On Isothermal Nucleic Acid Amplification Technology (INAAT) Market  Analysis:
www.grandviewresearch.com/industry-analysis/isothermal-nucleic-acid-amplification-technology-inaat-market

Further Key Findings From the Report Suggest:

·         Reagents are expected to be fastest growing products owing to their high usage in all INAAT procedures

·         TMA was identified as the largest technology segment by revenue share in 2016 owing to its high adoption

·         Infectious disease diagnostics is expected to be the fastest growing application owing to development of numerous assays for detection of specific infectious diseases

·         Hospitals dominated the end user segment in 2016 with the largest share and are expected to be continue dominance over the forecast period owing to the high usage of INAAT in hospitals globally

·         North America held the largest share of the global market in 2016, and the U.S. held the largest revenue share in the region owing to rise in infectious diseases, availability of government funds, prevalence of cancer, application of MDx in cancer screening & genetic disorders, and self-monitoring techniques

·         The molecular diagnostics industry in Asia Pacific is projected to witness substantial growth over the next decade due to various developments in major economies, especially in the NASBA, NEAR, and HDA technology segments

·         Some of the key players in the INAAT market include Alere; bioMerieux SA; Eiken Chemical Co. Ltd.; Hologic, Inc. (Gen-Probe); Lucigen; QIAGEN; Quidel Corporation; ThermoFisher Scientific; and Becton, Dickinson & Company

·         Major players have been engaging in numerous strategic initiatives such as mergers and acquisitions to increase global presence and improve market share.

Browse More Reports Of This Category By Grand View Research At:  www.grandviewresearch.com/industry/clinical-diagnostics

Grand View Research has segmented the global INAAT market on the basis of product, technology, application, end-use, and region:

Isothermal Nucleic Acid Amplification By Product Outlook (Revenue, USD Million, 2014 - 2025)

·         Instrument

·         Reagent

Isothermal Nucleic Acid Amplification By Technology Outlook (Revenue, USD Million, 2014 - 2025)

·         NASBA

·         HDA

·         LAMP

·         SDA

·         SPIA

·         NEAR

·         TMA

·         RCA

·         RPA

·         SMAP2

·         Others

Isothermal Nucleic Acid Amplification By Application Outlook (Revenue, USD Million, 2014 - 2025)

·         Blood screening

·         Infectious disease diagnostics

·         Cancer

·         Others

Isothermal Nucleic Acid Amplification By End Use Outlook (Revenue, USD Million, 2014 - 2025)

·         Hospitals,

·         Central and reference labs

·         Others

Regional Outlook (Revenue, USD Million, 2014 - 2025)

·         North America

o    U.S.

o    Canada

·         Europe

o    UK

o    Germany

·         Asia Pacific

o    China

o    India

o    Japan

·         Central & South America

o    Brazil

o    Mexico

·         Middle East & Africa

o    South Africa

Access Full Press Release of this Report:

www.grandviewresearch.com/press-release/global-isothermal-nucleic-acid-amplification-technology-inaat-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more information: www.grandviewresearch.com/

Cardiac Biomarkers Market Expected To Trigger A Revenue Increase To USD 13.3 Billion By 2024:Key Participant Alere, Inc., Siemens Healthcare GmbH

San Francisco, 10 October 2018, The Cardiac Biomarkers Market is expected to reach USD13.3 billion by 2024, according to a new report by Grand View Research, Inc. The cardiac biomarkers market is anticipated to witness a lucrative growth during the forecast period from 2016 to 2024.
Analysis of global market trends focuses on the increasing demand for cardiac biomarkers owing to its increased adoption in cardiovascular disease diagnosis. Furthermore, this growth is attributed to a majority of factors, such as the high prevalence of Acute Coronary Syndrome (ACS), continual technological advancements in the development of cardiovascular biomarkers, increasing number of new product launches by the key market players, rising demand for point of care cardiac testing kits, along with the high specificity and sensitivity of these biomarkers in the detection of cardiovascular diseases, especially acute myocardial infarction.
The cardiac biomarkers market has been classified by type into troponin, Creatine kinase-MB(CK-MB), B-type Natriuretic Peptide (BNP), and N-terminal pro b-type natriuretic peptide (NT-proBNP), myoglobin, and others. Troponin is a heteromeric protein and comprises cardiac troponin T & I, which are abbreviated as cTnT & cTnI, respectively. The troponin biomarkers segment is expected to grow lucratively in the forecast period at a significant CAGR. The diagnostic efficiency and specificity related to cardiac biomarker testing renders it a universally gold standard test to diagnose cardiovascular disorders worldwide. The market by application is segmented into acute coronary syndrome, myocardial infarction, congestive heart failure, and others. ACS is expected to be the highest grossing segment according to the study. ACS is responsible for huge medical costs globally and is responsible for most hospital readmission cases. The increasing efforts to cut down worldwide ACS prevalence rates are expected to drive the growth of the biomarkers market.
The key countries included in the report are U.S., Canada, Germany, UK, China, India, Brazil, Mexico, South Africa, and the Middle East. North America accounted for the largest market in 2015, whereas the Asia Pacific region is anticipated to be the fastest growing region during the forecast period.
Full Research Report On cardiac biomarkers market Analysis:www.grandviewresearch.com/industry-analysis/cardiac-biomarker-market

 Further key findings from the study suggest:

• North America is estimated to dominate the global cardiac biomarkers market. The high prevalence of coronary heart disease in western countries is one of the major factors contributing to the high demand for cardiac biomarker diagnostics.
• The Asia Pacific region is anticipated to be the fastest growing region in the study period owing to the large population, especially in China and India. Apart from that, there exists a high prevalence rate of myocardial infarction in the region. This prevalence rate is expected to fuel the demand for cardiac biomarker diagnostics.
• The troponin biomarker segment is expected to grow at a significant rate, and is expected to grow at the highest CAGR compared to others and accounts for the largest market share in 2015.
• The sector comprises of several local as well as global players. Some of the major players of this vertical include Alere, Inc., Siemens Healthcare GmbH, Roche Diagnostics, Beckman Coulter, Inc., Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, and bioMerieux SA.

Browse More Reports Of This Category By Grand View Research At:   www.grandviewresearch.com/industry/clinical-diagnostics
Grand View Research has segmented the cardiac biomarkers market on the basis of type, application, end use, and region:
Cardiac Biomarkers Type Outlook (Revenue, USD Million, 2013 - 2024)

• Troponin
• CK-MB
• Natriuretic peptides - BNP and NT-proBNP
• Myoglobin
• Others

Cardiac Biomarkers Market Application Outlook (Revenue, USD Million, 2013 - 2024)

• Acute Coronary Syndrome
• Myocardial infarction
• Congestive heart failure
• Others

Cardiac Biomarkers Market End-use Outlook (Revenue, USD Million, 2013 - 2024)

• Laboratory Testing
• Point of Care Testing

Cardiac Biomarkers Regional Outlook (Revenue, USD Million, 2013 - 2024)

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
• Asia Pacific
  • China
  • India
• Latin America
  • Brazil
  • Mexico
• MEA
  • South Africa
  • Middle East

  Access Full Press Release of this Report: https://www.grandviewresearch.com/press-release/global-cardiac-biomarker-market
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
For more information: www.grandviewresearch.com/